About Broad Street Alerts: — VCIL– Article_Below
Big opportunities in Small Cap’s
NOTE***** OPMZ is a an MMJ tech company with disruptive tech in the medical cannabis field and on high alert today as momentum is building!
Up over 30% and just getting started
As this week progresses we believe the BUZZ and momentum around OPMZ will definitely continue.
Full OPMZ Report- https://broadstreetalerts.com/wp-content/uploads/2016/03/OPMZ-profile.pdf
December 29th, 2015- (NASDAQ: INVT) opened $1.35/share hit a high midday of $2.82/share over 100%
in gains for our members
December 15th, 2015-(NYSE-MKT: XXII) opened at $1.29 hit a high of $1.54 within 3 days for gains of
19% for our members.
December 2nd, 2015- (NASDAQ: TCCO) opened at $3.25 hit a high of $4.50 within 3 days for 38% gains
for our members.
***IN PLAY- Current profile sent at 3pm on March 24th, 2016 to our members up 17% so far (NASDAQ:
ICLD) full profile- https://broadstreetalerts.com/wp-content/uploads/2016/03/ICLD-profile.pdf
These are numbers that make traders drool. Any trader in any market would fall all over themselves to
see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and
verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest
of the small-cap newsletters as the best in business. We know with a large following comes a large
responsibility as we have everyone from institutional investors to the beginner following our profiled
securities in our newsletters. This is something we take very seriously always seeking small cap growth
companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our
VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your
cell phone.
VCIL – Article
Vical Incorporated (Nasdaq: VICL) announced that the U.S. Food and Drug Administration (FDA) has granted Vical Fast Track designation for its investigational antifungal product candidate, VL-2397, for the treatment of invasive aspergillosis. The FDA’s Fast Track program is designed to expedite the development and review of drugs intended to treat serious conditions and fill an unmet medical need.
“New therapeutic options are needed to treat invasive aspergillosis, which continues to be a major source of morbidity and mortality in immunocompromised patients,” said Larry R. Smith, Ph.D., Vical’s Vice President of Vaccine Research. “The Fast Track designation for VL-2397, in addition to the qualified infectious disease product (QIDP) and the orphan drug designations already granted by the FDA, can facilitate expedited development of VL-2397. We believe VL-2397 has the potential to make a meaningful impact in the treatment of patients with systemic fungal infections such as aspergillosis.”
In preclinical studies to date, VL-2397 has demonstrated faster antifungal activity than marketed drugs and activity against azole-resistant fungal pathogens. Vical initiated a Phase 1 clinical trial of VL-2397 in March 2016. The randomized, double-blind trial will evaluate safety, tolerability and pharmacokinetics of VL-2397 at single and multiple ascending doses in healthy volunteers at a single U.S. clinical site.
Source: Street Insider
SCS LLC has not been compensated for this article.
SCS LLC was previously compensated up to twenty thousand dollars each by star media llc for the mention of INVT and XXII however those contracts have expired.
